

Adamas Pharmaceuticals Inc  
 Form 4  
 April 22, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Went Gregory T

2. Issuer Name and Ticker or Trading Symbol  
 Adamas Pharmaceuticals Inc  
 [ADMS]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
 04/20/2015

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 Chief Executive Officer

C/O ADAMAS  
 PHARMACEUTICALS, INC., 1900  
 POWELL ST., SUITE 750

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

EMERYVILLE, CA 94608

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
				(A) or (D)	Price					
				Code	V	Amount				
Common Stock	04/20/2015		M		2,610	A	\$ 1.875	22,618 <sup>(1)</sup>	D	
Common Stock	04/20/2015		S		2,610	D	\$ 18.0002 <sup>(2)</sup>	20,008 <sup>(1)</sup>	D	
Common Stock	04/20/2015		S		5,200	D	\$ 18.0002 <sup>(2)</sup>	397,103 <sup>(1)</sup>	I	Gregory T Went & Marjorie S Went tees Went

Edgar Filing: Adamas Pharmaceuticals Inc - Form 4

Common Stock	04/21/2015	M	962	A	\$ 1.875	20,970 <sup>(1)</sup>	D		Family Living Trust dtd 03/24/11
Common Stock	04/21/2015	S	962	D	\$ 18.0064 <sup>(3)</sup>	20,008 <sup>(1)</sup>	D		
Common Stock	04/21/2015	S	1,811	D	\$ 18.0024 <sup>(3)</sup>	395,292 <sup>(1)</sup>	I		Gregory T Went & Marjorie S Went ttees Went Family Living Trust dtd 03/24/11
Common Stock						6,666	I		Gregory T Went Cust - Bridget Went Under CA Uniform Transfers to Minors Act
Common Stock						6,666	I		Gregory T Went Cust - Cora Went Under CA Uniform Transfers to Minors Act
Common Stock						80,000	I		Gregory T Went & Marjorie S Went ttees 2012 Irr Trust FBO Bridget Elise Went
Common Stock						80,000	I		Gregory T Went &

Marjorie S  
Went tees  
2012 Irr  
Trust FBO  
Cora  
Margaret  
Went

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Stock Option (Right to Buy)	\$ 1.875	04/20/2015		M	2,610	<sup>(4)</sup> 09/12/2016	Common Stock	2,610
Stock Option (Right to Buy)	\$ 1.875	04/21/2015		M	962	<sup>(4)</sup> 09/12/2016	Common Stock	962

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Went Gregory T C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL ST., SUITE 750 EMERYVILLE, CA 94608	X	X	Chief Executive Officer	

## Signatures

/s/Grace Shin, as  
Attorney-in-Fact

04/22/2015

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

This transaction was executed in multiple trades at prices ranging from \$18.00 to \$18.005. The price reported above reflects the weighted

(2) average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

This transaction was executed in multiple trades at prices ranging from \$18.00 to \$18.04. The price reported above reflects the weighted

(3) average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

(4) This option is fully vested and exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.